Effects Of Neurostan On The Medication Compliance In Secondary Prevention For Coronary Heart Disease Patients With Anxiety And Depression

Objective:To analyze the present situation of secondary prevention medication for coronary heart disease patients and the effects of anxiety and depression on medication compliance, to investigate the improving degree of anxiety and depression and the effects of Neurostan on the secondary prevention medication for the coronary heart disease patients with anxiety and depression and provide evidence for improving the medication compliance in secondary prevention of coronary heart disease.Methods:An investigation on the medication compliance in secondary prevention of coronary heart disease and grading of Zung self-rating anxiety scale(SAS) and Zung self-rating depression scale(SDS) were carried out on 412 patients who were hospitalized and diagnosed with acute coronary syndrome and stable condition of more than 3 months and the effects of anxiety and depression on the secondary prevention medication compliance of coronary heart disease were analyzed. Coronary heart disease patients with simple anxiety(80 cases) and simple depression(80 cases) meeting the inclusion criteria were respectively divided into a control group with 40 cases and a treatment group with 40 cases employing a random number table. Neurostan was added to the treatment group, 300 mg each time, three times a day orally, while placebos was added to the control group, one tablet each time daily three times orally. After continuous treatment for eight weeks, scores of SAS and SDS before and after treatment were compared and the changes of medication compliance in secondary prevention for coronary heart disease were analyzed.Results:1. Total medication compliance in secondary prevention for the coronary heart disease patients: 64.3% of aspirin, 67.5% of statins, 44.9% of ACEI/ARB, and 42.7% of β receptor blocker.2. Accompanied simple depression patients’ medication compliance above were 61.8%, 62.9%, 48.3% and 43.8% respectively and it had statistical differences(P<0.05) compared with that of the patients without anxiety and depression(73.1%, 76.0%, 61.4%, 57.3%); accompanied simple anxiety patients’ medication compliance above were 62.7%, 64.9%, 48.7% and 45.6% respectively and it had no statistical differences(P>0.05) with that of the patients without anxiety and depression.3. The prevalence of the coronary heart disease with anxiety was 36.9%, and the prevalence of depression was 39.1%.4. After Neurostan treatment for eight weeks, scores of both SAS(42.23±5.27 vs. 54.23±7.92) and SDS(43.14±5.21 vs. 52.23±5.74) in the treatment group were obviously lower than those before treatment(P<0.05).5. After Neurostan treatment for eight weeks, accompanied simple anxiety patients’ medication compliance above were 67.1%, 69.2%, 53.5% and 50.1% respectively, while accompanied simple anxiety patients’ medication compliance above were 72.8%, 75.1%, 60.1% and 56.5% respectively. Compared with the medication compliance before treatment, all of them were improved to varying extents but had no statistical differences(P>0.05).Conclusion:1. The medication compliance in secondary prevention for patients is poor and the anxiety and depression affect the medication compliance in secondary prevention of coronary heart disease.2. The prevalence of the coronary heart disease with anxiety and depression is high and neurostan markedly improve the symptoms of anxiety and depression in patients with coronary heart disease.3. Neurostan might improve the medication compliance in secondary prevention for coronary heart disease in the patients with coronary heart disease combined with anxiety and depression.